Smart Assays

Executive Summary

Smart Assays is a GLP-certified contract research organization (CRO) based in Rehovot, Israel, founded in 2005. The company operates a 350 m² state-of-the-art facility offering high-throughput assay platforms in immunology, cell biology, histopathology, and bioanalytics. It provides tailored R&D support from early proof-of-concept through clinical-stage validation, positioning itself as a reliable partner for pharmaceutical and biotech firms. With a 50-200 employee team and a focus on quality, Smart Assays benefits from the growing trend of outsourcing preclinical and clinical development services, particularly in immuno-oncology and cell therapy. The company's established track record and scalable platform suggest steady revenue growth potential, though financial details are limited due to private ownership. Overall, Smart Assays represents a stable, niche CRO with opportunities for expansion into adjacent therapeutic areas.

Upcoming Catalysts (preview)

• Q3 2026Expansion of service offerings into gene therapy or cell therapy assay support70% success
• Q4 2026New strategic partnership with a major pharmaceutical company for multi-year contract60% success
• Q2 2026Facility expansion or acquisition to increase capacity and service scope50% success